Therapeutic Asset Ratings
132 results matching 1 filter
133,990 assets · 8,802 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Cyclophosphamide
Metastatic Solid Tumor
InSilico Medicine Hong Kong Limited
P2
CCC
(55)
Epirubicin
Metastatic Solid Tumor
InSilico Medicine Hong Kong Limited
P2
CCC
(55)
Pembrolizumab
Metastatic Solid Tumor
InSilico Medicine Hong Kong Limited
P2
CCC
(55)
Nivolumab
Metastatic Solid Tumor
Lantern Pharma Inc.
P2
CCC
(54)
Trastuzumab Emtansine
Metastatic Solid Tumor
M.D. Anderson Cancer Center
P2
CCC
(52)
prt3789
Metastatic Solid Tumor
Prelude Therapeutics
P2
CCC
(51)
Cetuximab
Metastatic Solid Tumor
Eli Lilly and Company
P1/2
CCC
(49)
Adebrelimab
Metastatic Solid Tumor
Second Affiliated Hospital of Soochow University
P2
CCC
(48)
Atezolizumab
Metastatic Solid Tumor
Second Affiliated Hospital of Soochow University
P2
CCC
(48)
Durvalumab
Metastatic Solid Tumor
Second Affiliated Hospital of Soochow University
P2
CCC
(48)
Gm-Csf
Metastatic Solid Tumor
Second Affiliated Hospital of Soochow University
P2
CCC
(48)
Lurbinectedin
Metastatic Solid Tumor
Jazz Pharmaceuticals
P2
CCC
(48)
Nab-Sirolimus
Metastatic Solid Tumor
Aadi Bioscience, Inc.
P2
CCC
(48)
Sugemalimab
Metastatic Solid Tumor
Second Affiliated Hospital of Soochow University
P2
CCC
(48)
Tucatinib
Metastatic Solid Tumor
M.D. Anderson Cancer Center
P2
CCC
(48)
Vesanoid
Metastatic Solid Tumor
University of Utah
P2
CCC
(48)
Fludarabine
Metastatic Solid Tumor
Acepodia Biotech, Inc.
P1/2
CC
(46)
gsk1120212
Metastatic Solid Tumor
Turning Point Therapeutics, Inc.
P1/2
CC
(46)
IMMUNOGLOBULIN G4, ANTI-(HUMAN PROGRAMMED CELL DEATH PROTEIN 1) (HUMAN MONOCLONAL REGN2810 HEAVY CHAIN), DISULFIDE WITH HUMAN MONOCLONAL REGN2810 .KAPPA.-CHAIN, DIMER
Metastatic Solid Tumor
Ankyra Therapeutics, Inc
P1/2
CC
(46)
Irinotecan
Metastatic Solid Tumor
MOMA Therapeutics
P1/2
CC
(46)
Olaparib
Metastatic Solid Tumor
Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd
P1/2
CC
(46)
Tislelizumab
Metastatic Solid Tumor
BeiGene
P1/2
CC
(46)
Trastuzumab Deruxtecan
Metastatic Solid Tumor
Lei Zheng
P1/2
CC
(46)
Repotrectinib
Metastatic Solid Tumor
Turning Point Therapeutics, Inc.
P1/2
CC
(45)
1.0% ip-001 for
Metastatic Solid Tumor
Immunophotonics, Inc.
P1/2
CC
(41)
Showing 1 to 25 of 132 assets
Previous
Page 1 of 6
Next
